➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Baxter
Express Scripts
Boehringer Ingelheim
Dow

Last Updated: October 28, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203434


Email this page to a colleague

« Back to Dashboard

NDA 203434 describes ACETAZOLAMIDE, which is a drug marketed by Accord Hlthcare, Alembic Pharms Ltd, Cadila, Heritage Pharma, Indicus Pharma, Micro Labs Ltd India, Mylan, Nostrum Labs Inc, Novast Labs, Alra, Appco, Ascot, Breckenridge, Eywa Pharma, Lannett, Mankind Pharma, Novitium Pharma, Rubicon, Strides Pharma, Sun Pharm Industries, Taro, Vangard, Watson Labs, Emcure Pharms Ltd, Hospira, Mylan Asi, Par Sterile Products, West-ward Pharms Int, Xgen Pharms, and Zydus Pharms, and is included in thirty-two NDAs. It is available from twenty-two suppliers. Additional details are available on the ACETAZOLAMIDE profile page.

The generic ingredient in ACETAZOLAMIDE is acetazolamide sodium. There are ten drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the acetazolamide sodium profile page.
Summary for 203434
Tradename:ACETAZOLAMIDE
Applicant:Novast Labs
Ingredient:acetazolamide
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 203434
Mechanism of ActionCarbonic Anhydrase Inhibitors
Medical Subject Heading (MeSH) Categories for 203434
Suppliers and Packaging for NDA: 203434
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ACETAZOLAMIDE acetazolamide CAPSULE, EXTENDED RELEASE;ORAL 203434 ANDA Ingenus Pharmaceuticals, LLC 50742-233 50742-233-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (50742-233-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength500MG
Approval Date:Sep 30, 2016TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Express Scripts
Baxter
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.